To review the pathogenesis of JAK-STAT pathway-associated skin diseases and the efficacy of JAK inhibitors (JAKi) therapy, while providing references for clinical diagnosis and treatment.
Key Findings:
The JAK-STAT signaling pathway is involved in various inflammatory and autoimmune skin diseases.
Small molecule JAK inhibitors, such as abrocitinib and upadacitinib, have shown substantial efficacy in treating inflammatory skin diseases.
Traditional classification of inflammatory skin diseases based on Th immune axis is inadequate for guiding targeted therapy.
Interpretation:
The JAK-STAT pathway serves as a common downstream signaling axis for multiple Th cell factors, facilitating a unified understanding of inflammatory skin diseases.
Limitations:
The traditional classification systems do not adequately explain disease heterogeneity and treatment responses, particularly regarding the implications of immunogenicity and logistical challenges associated with biologics.
Conclusion:
A refined framework for understanding JAK-STAT pathway-associated skin diseases may improve mechanistic understanding and clinical application of JAK inhibitors, potentially enhancing treatment outcomes.
